天然产物研究与开发 ›› 2022, Vol. 34 ›› Issue (6): 1057-1066.doi: 10.16333/j.1001-6880.2022.6.019

• 数据研究 • 上一篇    下一篇

基于网络药理学研究6-姜辣素改善L6成肌细胞糖脂代谢紊乱的作用机制

曾   颜1,田珈瑜2,詹权操2,刘宇哲1,李   冬2,王   尚2*,王建伟1*   

  1. 1重庆医科大学基础医学院;2重庆医科大学中医药学院 中医药防治代谢性疾病重庆市重点实验室,重庆 400016
  • 出版日期:2022-06-28 发布日期:2022-06-30

Mechanism of 6-gingerol alleviating glycolipid metabolism disorder in L6 cells based on network pharmacology

ZENG Yan1,TIAN Jia-yu2,ZHAN Quan-cao2, LIU Yu-zhe1,LI Dong2,WANG Shang2*,WANG Jian-wei1*   

  1. 1Faculty of Basic Medical Sciences,Chongqing Medical University; 2Chongqing Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Metabolic Diseases,College of Traditional Chinese Medicine,Chongqing Medical University,Chongqing 400016,China
  • Online:2022-06-28 Published:2022-06-30

摘要:

运用网络药理学研究6-姜辣素改善糖脂代谢紊乱的作用机制,并通过高果糖高油酸培养的L6大鼠成肌细胞模型进行验证。借助TCMSP数据库、SwissTargetPrediction数据库、GeneCards数据库,对6-姜辣素作用糖脂代谢紊乱的靶点进行预测,运用软件Cytoscape 3.7.1构建化合物靶点-疾病网络关系,采用STRING数据库进行蛋白质-蛋白质相互作用(protein-protein interaction,PPI)分析,利用R包进行GO功能富集和KEGG通路富集分析;运用KEGG Mapper对富集基因进行基因映射。结合GO富集分析、KEGG通路分析和基因映射结果,该研究选择PI3K-AKT信号通路、mTOR、NF-κB-p65、ERK分子进一步进行体外实验验证。通过高果糖高油酸构建L6大鼠成肌细胞糖脂代谢紊乱模型,对细胞进行甘油三酯(TG)测定和油红染色,蛋白免疫印迹法(Western blot)检测炎症相关蛋白IL-1β、TNF-α的表达,实时荧光定量聚合酶链式反应(real time polymerase chain reaction,RT-PCR)和蛋白免疫印迹法检测6-姜辣素对PI3K-AKT信号通路、mTOR、NF-κB-p65、ERK分子的基因、蛋白表达的影响。网络药理学分析共得到6-姜辣素治疗糖脂代谢紊乱靶点113个,GO富集分析发现与蛋白质激酶活性关系密切,KEGG富集共筛选出20条相关信号通路,包括PI3K-AKT信号通路、乙型肝炎、丙型肝炎、人类巨细胞病毒感染、自噬等。体外实验表明6-姜辣素能减少高果糖高油酸诱导的L6细胞脂质积累,减少炎症相关蛋白IL-1β、TNF-α的表达,上调AKT的基因和蛋白磷酸化水平,下调mTOR、NF-κB-p65、ERK的磷酸化水平。这些结果提示6-姜辣素能够改善高果糖高油酸诱导的L6大鼠成肌细胞糖脂代谢紊乱,其机制可能与激活PI3K-AKT-mTOR轴改善胰岛素敏感性和抑制NF-κB-p65、ERK的磷酸化降低炎症反应有关,这为后续的基础研究提供理论基础。

关键词: 6-姜辣素, 糖脂代谢紊乱, 网络药理学, L6大鼠成肌细胞

Abstract:

The mechanism of 6-gingerol in improving glycolipid metabolism disorders was investigated by network pharmacology and confirmed by L6 cells cultured with high fructose and high oleic acid.Using TCMSP database,SwissTargetPrediction database and GeneCards database,the targets of 6-gingerol on glycolipid metabolism disorder were obtained,Cytoscape 3.7.1 was used to construct the relationship between compound target and disease network,protein-protein interaction (PPI) was analyzed using STRING database,GO functional enrichment and KEGG pathway enrichment through R packet,and gene mapping was carried out by KEGG Mapper.Combined with GO enrichment analysis,KEGG pathway analysis and gene mapping results,this study selected the PI3K-AKT-mTOR axis,NF-κB-p65 and ERK in vitro.The model of glycolipid metabolism disorder in L6 cells were established by high fructose and high oleic acid.TG and oil red staining were used to assess lipid deposition level and Western blot was used to detect the expression of inflammatory factors IL-1β and TNF-α.RT-PCR and western blot were used to detect the levels of mRNA and protein associated with PI3K-AKT- mTOR,NF-κB-p65 and ERK.A total of 113 targets for 6-gingerol treatment of glucolipid metabolism disorders were identified by network pharmacologic analysis.GO enrichment analysis showed that 6-gingerol was closely related to protein kinase activity.A total of 20 KEGG signaling pathways were screened including PI3K-AKT signaling pathway,hepatitis B,hepatitis C,human cytomegalovirus infection,autophagy,etc. In vitro experiments showed that 6-gingerol could reduce lipid accumulation in L6 cells induced by high fructose and high oleic acid and the expression of pro-inflammatory factors IL-1β and TNF-α.Meanwhile,6-gingerol could up-regulate the expression of phosphorylation of AKT,and down-regulate the expression of phosphorylation of mTOR,NF-κB-p65 and ERK.In addition,6-gingerol could increase the expression of AKT at mRNA level.These results suggest that 6-gingerol can improve glucolipid metabolism disorder in L6 cells treated with high fructose and high oleic acid,and relate to activate PI3K-AKT-mTOR axis and inhibit inflammation through blocking phosphorylation of NF-κB-p65 and ERK.These findings provide theoretical basis for subsequent basic research.

Key words: 6-gingerol, glycolipid metabolism disorder, network pharmacology, L6 cells

中图分类号:  R285